Abstract
New advances in effective mobilization of peripheral blood stem cells have permitted a greater proportion of patients to benefit from autologous stem cell transplantation. In this review, the relative merits of peripheral blood and mobilized bone marrow are discussed. All available agents are reviewed. A critical assessment of the appropriate dosing and frequency of available growth factors is undertaken, and the most commonly used chemotherapy plus growth factor combinations are covered. Specific recommendations for patients who are poor mobilizers are dealt with including the role of plerixafor.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 647-662 |
| Number of pages | 16 |
| Journal | British journal of haematology |
| Volume | 150 |
| Issue number | 6 |
| DOIs | |
| State | Published - Sep 2010 |
Keywords
- growth factors
- mobilization
- multiple myeloma
- non-Hodgkin lymphoma
- stem cell transplantation
ASJC Scopus subject areas
- Hematology